Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics (NASDAQ:SRPT) surges 40% post-market after strategic restructuring, workforce cuts, pipeline focus, and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops ...